This is a regenerative biomedical technology, which aims to address the human chronic lung diseases that currently has no pharmaceutical approach for efficient controltherapy, such as COPDlung fibrosis. The principle is to induce the in vivo reprogramming of endogenous alveolar epithelial cells through activation of stemness factor BMI1, which potentiates the repair of injured tissues.